Security National Bank of SO Dak Invests $200,000 in Amgen Inc. (NASDAQ:AMGN)

Security National Bank of SO Dak acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 643 shares of the medical research company’s stock, valued at approximately $200,000.

Several other large investors have also modified their holdings of AMGN. Capital World Investors boosted its position in shares of Amgen by 1,292.0% in the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the period. Norges Bank acquired a new stake in shares of Amgen in the fourth quarter worth $1,541,991,000. GAMMA Investing LLC boosted its position in shares of Amgen by 43,573.5% in the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock worth $1,140,768,000 after buying an additional 3,653,205 shares during the period. Capital International Investors boosted its position in shares of Amgen by 40.1% in the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Amgen by 52.7% in the fourth quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company’s stock worth $858,020,000 after buying an additional 1,135,884 shares during the period. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 0.5%

AMGN stock opened at $298.25 on Monday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a market cap of $160.37 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 2.70 and a beta of 0.49. The business’s 50-day simple moving average is $282.47 and its 200 day simple moving average is $287.17. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the business earned $3.96 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. On average, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on AMGN. Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. Royal Bank Of Canada cut their price objective on Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Piper Sandler reiterated an “overweight” rating and set a $328.00 price objective on shares of Amgen in a report on Friday, June 27th. Morgan Stanley reiterated an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. Finally, Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 18th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $307.82.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the sale, the senior vice president directly owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.